Thursday 7th November 2019

Cancer genetic counseling

o8:00 a.m. Registration and coffee/tea

09:00 a.m. Welcome

Session 1 – Polygenic risk scores and panel testing

og:10 a.m. Antonis Antoniou (University of Cambridge, UK): Future-proofing breast

cancer risk prediction

og:40 a.m. <u>Inge M.M. Lakeman (Leiden UMC, NL):</u> Clinical applicability of the 313-SNP

based polygenic risk score for breast cancer risk prediction

10:00 a.m. <u>Iris Kramer (NCI, Amsterdam, NL):</u> Association between a breast cancer

polygenic risk score and contralateral breast cancer risk

10:20 a.m. <u>Thomas P. Potjer (Leiden UMC, NL):</u> Association between polygenic risk score

and melanoma risk in 418 Dutch melanoma families

10:35 a.m. Coffee/tea break

11:15 a.m. Peter Devilee (Leiden UMC, NL): International Bridges-project on high-risk in

non-carrier women

Session 2 – Psychosocial and counseling aspects

11:45 a.m. <u>D. Gareth Evans (Manchester University NHS FT, UK):</u> Uptake of pre-

symptomatic testing for BRCA1 and BRCA2 is age, gender and time dependent

is increased by having children

12:05 p.m. Nicci Bartley (University of Sydney, AU): Fear of cancer recurrence and

uncertainty in patients undergoing whole genome sequencing

12:25 p.m. Caroline Willems and Désirée Hairwassers (Oncogen/ Breast Cancer

Association, NL): What your patients didn't get

12:55 p.m. Lunch break and poster sessions

o2:00 p.m. <u>Eveline M.A. Bleiker (NCI, Amsterdam, NL):</u> Implementing a tool to improve

communication on psychosocial issues in cancer genetics

o2:15 p.m. <u>Allison Werner-Lin (University of Pennsylvania, US):</u> Complicated grief in family

life with Li-Fraumeni Syndrome

o2:30 p.m. <u>Miranda P. Steenbeek (Radboudumc, Nijmegen, NL):</u> Worry and regret in the

prospective multicentre TUBA study in BRCA1/2 mutation carriers



o2:45 p.m. <u>Lieske H. Schrijver (NCI, Amsterdam, NL):</u> Psychosocial issues in men tested for

BRCA_{1/2} mutations

o3:00 p.m. <u>Madeleine M.A. Tilanus-Linthorst (Erasmus MC, Rotterdam, NL):</u> First benefit

and cost of FaMRIsc, a RCT comparing mammography with MRI in screening for

familial risk

o3:15 p.m. <u>Marthe M. de Jonge (Leiden UMC, NL):</u> Uterine cancer risk in women with

germline BRCA1 and BRCA2 mutations

03:30 p.m. Coffee/tea break

Session 3 – Mainstreaming of cancer genetics

04:15 p.m. <u>Michelle Bowman (Westmead Hospital, Sydney, AU):</u> Mainstream genetic

testing: Reflections on the first year at Westmead

o4:30 p.m. Sook-Yee Yoon (Cancer Research Malaysia, MY): Experiences with

mainstreaming in Malaysia

o5:00 p.m. <u>Kyra Bokkers (UMC Utrecht, NL):</u> A gynecological oncologist-led

mainstreaming approach of germline genetic testing for patients with ovarian

cancer; first experiences of healthcare professionals and patients

o5:15 p.m. <u>Heamanthaa Padmanabhan (Cancer Research Malaysia, MY):</u> Decisional

conflict, genetic counseling satisfaction and clinicians' feedback from a mainstreaming BRCA1 and BRCA2 genetic testing study in Malaysia

o5:30 p.m. Closing

o5:35 p.m. Drinks

o6:00 p.m. Optional -CORPUS experience: 'Journey through the human body'

07:30 p.m. Buffet dinner



Friday 8th November 2019

Counseling aspects of hereditary cancer

o8:00 a.m. Registration and coffee/tea

09:00 a.m. Welcome

og:10 a.m. Elizabeth Bancroft (The Royal Marsden NHS Foundation Trust, London, UK):

Germline predisposition to prostate cancer - clinical and psychosocial aspects

Session 1 – Lynch syndrome

og:40 a.m. Albert S. Tjalsma (Erasmus MC, Rotterdam, NL): Implementation of a

nationwide guideline to detect women at risk for Lynch Syndrome in

endometrial cancer should be improved

10:00 a.m. <u>Karen Hurley (Cleveland Clinic, US):</u> Time from genetic test result to first

colonoscopy in Lynch patients with personal/family history of breast and/or

gynecologic cancers

10:20 a.m. <u>Janet R. Vos (Radboudumc, Nijmegen, NL):</u> Age related identification of Lynch

Syndrome patients among patients with mismatch repair deficient colorectal

cancer

10:40 a.m. Coffee/tea break

12:45 p.m.

Session 2 – Health literacy and family issues

11:25 a.m. Margreet G.E.M. Ausems (UMC Utrecht, NL): Limited health literacy and

access to cancer genetic counseling

11:55 a.m. Fred H. Menko (NCI, Amsterdam, NL): The uptake of predictive DNA-testing in

40 BRCA1/BRCA2 mutation-positive families. An evaluation of the standard

proband-mediated procedure

12:10 p.m. <u>Jeanine A.M. van der Giessen (UMC Utrecht, NL):</u> Evaluation of a training

program for healthcare professionals to improve communication about genetic

testing with breast cancer patients with limited health literacy

12:30 p.m. Wendy A.G. van Zelst-Stams (Radboudumc, Nijmegen, NL): Who is responsible

for informing relatives of carriers: update of the Dutch guideline

Maaike L. Haadsma (Radboudumc, Nijmegen, NL): Informing family members

about predisposition for hereditary cancer: A proactive and personalized

approach

01:00 p.m. Lunch break and poster sessions

o2:00 p.m. Megan Best (University of Sydney, AU): Cancer patient knowledge and

attitudes towards whole genome sequencing



Session 3- Risk factors

o2:15 p.m. Karen Basen-Engquist (MD Anderson, Houston, US): Motivating change of

lifestyle behavior in high risk families

o2:45 p.m. <u>Daniele Giardiello (NCI, Amsterdam, NL):</u> Prediction and clinical utility of a

contralateral breast cancer risk model

03:05 p.m. <u>Mark van Barele (Erasmus MC, Rotterdam, NL):</u> The association between

radiotherapy and contralateral breast cancer risk in young BRCA1/2-associated

breast cancer patients

o3:20 p.m. Frederieke van der Baan (NCI/ UMC Utrecht, NL): Change of breast density

after a risk reducing salpingo oophorectomy for BRCA1 and BRCA2 mutation

carriers

03:40 p.m. Coffee/tea break

o4:20 p.m. <u>Jan Brouwer (UMC Groningen, NL):</u> Risk factors for high-grade serous

carcinoma in BRCA1/2 mutation carriers undergoing risk-reducing salpingo-

oophorectomy – A preliminary report from the Dutch nationwide HEBON study

04:40 p.m. <u>Lise M. van Wijk (Leiden UMC, NL): Functional</u> analysis of BRCAness in ovarian

cancer

Session 4 - Future genetic testing

o4:55 p.m. Sibel Saya (University of Melbourne, AU): The acceptability and feasibility of

assessing colorectal cancer risk using genomic testing to target screening in

general practice

o5:10 p.m. Rolf Sijmons (UMC Groningen, NL): Direct to consumer testing, the way to go?

05:40 p.m. Best poster awards

05:55 p.m. Closing

o6:00 p.m. Drinks